![Hero Primary](/my/sites/default/files/2024-02/Hero%20Primary.png)
Unlocking the Next Chapter of Kidney Care
Treating and Managing CKD
Goals in CKD treatment includes Slowing down Kidney Disease Progression, Reducing Mortality Risk and Managing Co Morbid conditions like Controlling blood sugar, Blood Pressure and maintaining normal lipid levels.
Guidelines
Below links to KDIGO Clinical Practice guidelines will help you optimally manage your CKD patients. Please tailor fit your management to your patients condition and integrate relevant local Guidelines.
![](/my/sites/default/files/2024-03/MicrosoftTeams-image%20%287%29.png)
KDIGO 2024 Clinical Practice
2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD)
![Diabetes Management in CKD Diabetes Management in CKD](/my/sites/default/files/2024-02/Diabetes-Management-in-CKD.png)
Diabetes Management in CKD
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
![Management of Blood Pressure in CKD Management of Blood Pressure in CKD](/my/sites/default/files/2024-02/Management%20of-Blood-Pressure%20in-CKD.png)
Management of Blood Pressure in CKD
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
![Lipid-Management in-CKD Lipid-Management in-CKD](/my/sites/default/files/2024-02/Lipid-Management%20in-CKD.png)
Lipid Management in CKD
KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease
Continuing Care, Referral and Co-management
Managing Patient with a Nephrologist provides opportunities to shared best care. Below are reasons to Refer a patient for Nephrology Consultation
- Unexplained, progressive decline in eGFR ≥5 mL/min/1.73 m² over 12 months or sudden decline in eGFR over days to weeks.
- Unexplained significant albuminuria/proteinuria or hematuria.
- Persistent hyperkalemia, resistant hypertension (defined as uncontrolled hypertension on three antihypertensive agents, including a diuretic), recurring kidney stones, or hereditary kidney diseases (e.g. ADPKD).
- Other complications identified (anemia, mineral and bone disorders, metabolic acidosis, etc.
References
-
1.
Sundström J et al. Lancet Reg Health Eur 2022; 20: 100438.
-
2.
Shlipak MG et al. Kidney Int 2021; 99 (1): 34–47.
-
3.
ADA/KDIGO Consensus Report: Diabetes Management in Chronic Kidney Disease. Diabetes Care 2022; In press Adapted from de Boer IH et al. Kidney International (2022).
-
4.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD)
-
5.
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
-
6.
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (kidney-international.org)
-
7.
KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. KDIGO-2013-Lipids-Guideline-English.pdf
Document ID: SC-MY-04974